Effect of pegylation on pharmaceuticals

Nature Reviews Drug Discovery

Volumn 2, Issue 3, 2003, Pages 214-221

  Milton Harris, J ^a   Chess, Robert B ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LIPOSOME; MACROGOL; NEUTRALIZING ANTIBODY; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYPEPTIDE; PROTEINASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; DRUG; MACROGOL DERIVATIVE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

DEVICE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; HYDROGEL; KIDNEY CLEARANCE; MOLECULAR WEIGHT; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETROSPECTIVE STUDY; REVIEW; ANIMAL; CHEMISTRY; CLINICAL TRIAL; METABOLISM; PHARMACOKINETICS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; HUMANS; HYDROGELS; PHARMACEUTIC AIDS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS;

EID: 0037362655     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1033     Document Type: Review

References (75)

1. Clark, A. Formulation of proteins and peptides for inhalation. Drug Deliv. Syst. Sci. (In the press).
2. Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476 (2002).
3. Mateo, C. et al. Removal of amphipathic epitopes from genetically-engineered antibodies: production of modified immmunoglobulins with reduced immunogenicity. Hybridoma. 19, 436-471 (2000).
4. Lyczak, J. B. & Morrison, S. L. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein. Arch. Virol. 139, 189-196 (1994).
5. Syed, S. et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 89, 3242-3252 (1997).
6. Allen, T. M. Liposomes: opportunities in drug development. Drugs 54 Suppl. 4, 8-14 (1997).
7. Sebeni, J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15, 57-88 (1998).
8. Bailon, P. & Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1, 352-356 (1998).
9. Zaplinsky, S. Harris, J. M. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 1-15 (San Francisco, 1997).
10. Gabizon, A. & Martin, F. Polyethylene glycol-coated liposomal doxorubicin. Drugs 54 Suppl. 4, 15-21 (1997).
11. Yamaoka, T., Tabata, Y. & Ikada, Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83. 601-606 (1994).
12. Working, P. K. et al. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 45-57 (San Francisco, 1997).
13. Richter, A. W. & Akerblom, E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethyleneglycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70, 124-131 (1983).
14. Cheng, T. et al. Acclerated clearance of polethylene glycol modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 10, 520-528 (1999).
15. Davis, F. F. et al. Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 4, 169-173 (1978).
16. Davis, F. F. et al. In Peptide and Protein Drug Delivery (ed Lee, V. H. L.) 226-231 (Marcel Dekker, New York, 1990).
17. Nucci, M. L., Schorr, R. & Abuchowski, A. The therapeutic value of polyethylene glycol modified protein. Adv. Drug Deliv. Rev. 6, 133-151 (1991).
18. Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539-551 (2001).
19. Kozlowski, A. & Harris, J. M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 72, 217-224 (2001).
20. Monfardini, C. et al. A branched monomethoxypolyethylene glycol for protein modification. Bioconjug. Chem. 6, 62-69 (1995).
21. Koslowski, A., Charles, S. A. & Harris, J. M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419-429 (2001).
22. Katre, N. V. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev. 10, 91-114 (1993).
23. Zaplinsky, S. & Lee, C.. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 347-370 (Plenum Press, NewYork, 1992).
24. Kinstler, O. B. et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 996-1002 (1996).
25. Zaplinsky, S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16, 157-182 (1995).
26. Harris, J. M. Synthesis of polyethylene glycol derivatives. J. Macromol. Sci. Rev. C25, 325-373 (1985).
27. Dust, J. M, Fang, Z. H. & Harris, J. M. Proton NMR characteristics of polyethylene glycol and derivatives. Macromolecules 23, 3742-3746 (1990).
28. Bentley, M. D. & Harris, J. M. Polyethylene glycol aldehyde hydrates and related polymers and applications in modifying. US Patent 5,990,237 (1999).
29. Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343-346 (1990).
30. El Tayar, N. et al. Polyo-IFN-β conjugates. WO 99/55377 (1999).
31. Zaplinsky, S. et al. New detachable polyethylene glycol conjugates:Cysteine-cleavable lipopolymers regenerating natural phospholipid. Bioconjug. Chem. 10, 703-710 (1999).
32. Yokoyama, M. et al. Synthesis of polyethylene oxide with heterobifunctional reactive groups at its terminals by an anionic inititator. Bioconjug. Chem. 3, 275-276 (1992).
33. Bentley, M. D., Harris, J. M. & Kozlowski, A. Heterobifunctional polyethylene glycol derivatives and methods for their preparation. WO 126692A1 (2001).
34. Yamasaki, N., Matsuo, A. & Isobe, H. Novel polyethylene glycol derivatives for modification of proteins. Agric. Biol. Chem. 52, 2125-2127 (1988).
35. Veronese, F. M. & Caliceti, P. Branched and linear polyethylene glycol influence of the polymer structure on enzymological, pharmacokinetic and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 12, 196-207 (1997).
36. Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency. Clin. Immunol. Immunopathol. 76, S228-232 (1995)
37. Burnham N. L. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51, 210-218 (1994).
38. Hillman, B. C. & Sorensen, R. U. Management options: SCIDS with adenosine deaminase deficiency. Ann. Allergy 72, 395-404 (1994).
39. Hershfield, M. S. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 145-154 (Plenum Press, NewYork, 1992).
40. Keating, M. J. et al. 1-asparaginase and PEG asparaginase - past, present, and future. Leuk. Lymphoma 10, 153-157 (1993).
41. Holle, L. M. Pegasparagase: an alternative. Ann. Pharmacother. 3, 616-624 (1997).
42. Physicians' Desk Reference, 53 edition 2600-2601 (Thomson PDR, Montvale, New Jersey, 1999).
43. Liang, J. T. et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000).
44. Grace, M. et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J. Interferon. Cytokine. Res. 21, 1103-1115 (2001).
45. Glue, P. et al. PEG-interferon-α2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatology 30, 189A (1999).
46. Linday, K. L. et al. A randomized double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395-403 (2001).
47. O'Brien, C. et al. A double-blind, mult-icenter randomized, parallel close-comparison study of six regimens of 5kD linear peginterferon α-2a compared with Roferon-A in patients with chronic hepatitis C. Antivir. Ther. 4, 15 (1999).
48. Bailon, P. et al. Pharmacological properties of five polyethylene glycol conjugates of interferon α-2a. Antivir. Ther. 4, 27 (1999).
49. Algranati, N. E., Sy, S. & Modi, M. A branched methoxy 40 kDa polyethylene glycol moiety optimizes the pharmacokinetics of PEG-IFN. Hepatology 30, 190A (1999).
50. Zeuzem, S. et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672 (2000).
51. Heathcote, E. J. et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673-1680(2000).
52. Liang, J. T. et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000).
53. McHutchinson, J. G. et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485-1492 (1998).
54. Poynard, T. et al. Randomized trial of interferon α-2b plus ribavirin for 48 weeks versus interferon α-2b placebo for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-1432 (1998).
55. Sulkowski, M. S. et al. Pegylated interferon α-2a and ribavirin combination therapy for chronic hepatitis C. Gastroenterology 118, 950 (2000).
56. Manns, M. P. et al. Peginterferon α-2b plus ribavirin compared to interferon α-2b plus ribavirin for the treatment of chronic hepatitis C. Lancet 358, 958-965 (2001).
57. Fried, M. W. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
58. Drake W. M. et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur. J. Endocninol. 145, 451-456 (2001).
59. Van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754-1759 (2001).
60. Edwards, C. K. PEGylated recombinant human soluble tumor necrosis factor receptor type I. Ann. Rheum. Dis. 58, 173-181 (1999).
61. Moreland, L. W. et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27, 601-609 (2000).
62. Choy E. H. et al. Efficacy of a novel pegylated humanized anti-tnf fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded randomized dose-escalating trial. Rheumatology 41, 1133-1137 (2002).
63. Crawford, J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev 28, 7-11 (2002).
64. Bence, A. K. & Adams, V. R. Pegfilgrastim: a new therapy to prevent neutropenic fever. J. Am. Pharm. Assoc. 42, 806-808 (2002).
65. Gordon, A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
66. Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95-99 (2002).
67. Zhao, X. & Harris, M. J. Novel degradable polyethylene glycol hydrogels for controlled release of protein. J. Pharm. Sci. 87, 1450-1458 (1998).
68. Gillinov, A. M. & Lytle, B. W. A novel synthetic sealant to treat air leaks at cardiac reoperation. J. Card. Surg. 16, 255-257 (2001).
69. Wain, J. C. et al. Trial of a novel synthetic sealant in preventing air leaks after lung resection. Ann. Thorac. Surg. 71, 1623-1628 (2001).
70. Ferland, R., Mulani, D. & Campbell, P. K. Evaluation of a sprayable polyethylene gylcol adhesion barrier in a porcine efficacy model. Human Reprod. 16, 2718-2723 (2001).
71. Hinds, K. D. & Skim, S. W. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54, 505-530 (2002).
72. Weir, A. N. et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30, 512-516 (2002)
73. Rocca, M. et al. Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischemia/reperfuslon injury. Int. J. Artif. Organs. 19, 730-734 (1996).
74. Calvo, P. et al. Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157-1165 (2001).
75. Shi, N. et al. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18, 1091-1095 (2001).